tiprankstipranks
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk
Company Announcements

Virpax Pharmaceuticals Faces Nasdaq Delisting Risk

Don't Miss our Black Friday Offers:

Virpax Pharmaceuticals ( (VRPX) ) just unveiled an update.

Virpax Pharmaceuticals has been notified by Nasdaq of not meeting the minimum bid price requirement of $1.00 for its common stock over the past 30 business days. The company will remain listed as it seeks to correct the deficiency by April 2, 2025, with the possibility of a 180-day extension. If unsuccessful, Virpax may face delisting but is considering measures such as a reverse stock split to regain compliance.

For an in-depth examination of VRPX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyVirpax Pharmaceuticals announces results from Probudur minipig DRF study
TheFlyVirpax Pharmaceuticals announces HHS pact over NES100 developmental extension
TipRanks Auto-Generated NewsdeskVirpax Pharmaceuticals Announces New Chief Financial Officer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App